GovWire

Public information about SCT screening is available on the NHS website.

There are no risks associated with screening for SCT. It can however provide information that may mean families have to make further important decisions. It is an individuals choice whether or not to be screened.

The SCT screening handbook for antenatal laboratories and handbook for newborn laboratories set out interpretation and reporting guidelines related to laboratory processes, including which types of carrier states to report.

There is guidance on DNA testing for transfused babies which sets out the recommendations and processes for offering DNA tests to babies who have had a blood transfusion before newborn blood spot screening.

The screening inequalities strategy sets out the commitment to reduce inequalities and variation in screening participation to help make sure everyone has fair and equal access to services.

Patient confidentiality in population screening programmes explains how and why population screening programmes collect and process data.

Target population

Antenatal screening

Sickle cell disease (SCD) screening is offered to:

• pregnant women
• fathers where antenatal screening shows the mother is a genetic carrier

SCD screening is offered to all pregnant women in high prevalence areas. This is done using a simple blood test.

In low prevalence areas, the family origin questionnaire (FOQ) is used to determine if a person is likely to be a carrier for SCD or other haemoglobin disorder.

All pregnant women are offered screening for thalassaemia.

All biological fathers are offered screening if the pregnant woman is a genetic carrier for sickle cell disease or thalassaemia.

There are special circumstances where additional investigations may be required.

Newborn screening

All newborn babies are offered sickle cell screening as part of the newborn blood spot screening programme, usually when they are 5 days old.

Conditions screened for

The programme screens for:

• genetic carriers for sickle cell, thalassaemia and other haemoglobin disorders
• SCD
• thalassaemia
• haemoglobin disorders

Screening tests

The following screening tests may be offered:

• a blood test for pregnant women and fathers

• a family origin questionnaire (FOQ)

• a heel prick test for newborn babies

Evidence base

SCT screening is one of 11 NHS national population screening programmes available in England.

The UK National Screening Committee (UK NSC) makes recommendations to ministers in the 4 UK countries on all aspects of population screening. It ensures that screening provides more benefit than harm, at a reasonable cost to the NHS.

Recommendations are based on internationally recognised criteria and a rigorous evidence review process.

There are separate UK NSC recommendations on:

• SCT screening in pregnancy
• SCD screening in newborns

Data and intelligence

See annual data collected from the linked antenatal and newborn SCT screening programme for data up to 31 March 2017.

For 1 April 2017 to 31 March 2021 data, see the joint antenatal screening standards data report.

For 1 April 2021 to 31 March 2022 data and onwards see our data collection page for Sickle cell and thalassaemia screening (SCT) standards reports

Key performance indicator (KPI) data reports are available for all 11 national screening programmes.

Requests for screening data and research

All requests for SCT screening data need to be approved by the antenatal and newborn (ANNB) screening research advisory committee (RAC).

See the 